Skip to main content

Table 4 Tumour response, progression and death

From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

  Total C1750 mg/m2 C1500 mg/m2
n = 49 n = 19 n = 30
Patient status at end of follow-up, n (%)
Alive, without disease progression 9 (18.4) 1 (5.3) 8 (26.7)
Alive with disease progression 19 (38.8) 9 (47.4) 10 (33.3)
Death after disease progression 15 (30.6) 6 (31.6) 9 (30.0)
Death without disease progression 6 (12.2) 3 (15.8) 3 (10.0)
Non measurable disease, n 6 2 4
Best overall response, n (%) n = 43 n = 17 n = 26
Complete response 2 (4.7) 1 (5.9) 1 (3.9)
Partial response 20 (46.5) 8 (47.1) 12 (46.2)
Stable disease 15 (34.9) 8 (47.1) 7 (26.9)
Progressive disease 5 (11.6) 0 (0.0%) 5 (19.2)
Died 1 (2.3) 0 (0.0%) 1 (3.9)
Complete or partial response (%, 95% CI) 51.2% (35.5, 66.7) 52.9% (27.8, 77.0) 50.0% (29.9, 70.0)
Confirmed response, n (%) n = 43 n = 17 n = 26
Complete response 2 (4.7) 1 (5.9) 1 (3.9)
Partial response 13 (30.2) 7 (41.2) 6 (23.1)
Stable disease 8 (18.6) 2 (11.8) 6 (23.1)
Progressive disease 15 (34.9) 5 (29.4) 10 (38.5)
Died 5 (11.6) 2 (11.8) 3 (11.5)
Confirmed complete or partial response (%, 95% CI) 34.9% (21.0, 50.9) 47.1% (23.0, 72.2) 26.9% (11.6, 47.8)